Catalog3 refs
PE-22-28 (Mini-Spadin)
Nootropic & NeuroResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Overview
Synthetic heptapeptide derived from Spadin positions 22-28, functioning as potent TREK-1 antagonist with enhanced selectivity and duration versus parent compound. Primary research focus on rapid antidepressant effects. Selectively blocks TREK-1 potassium channels (IC50: 0.12 nM). Enhances serotonin neurotransmission in dorsal raphe nucleus, triggering CREB activation and hippocampal neurogenesis. 300-500x greater potency than full-length Spadin.
Primary Uses
Rapid antidepressant effects
Hippocampal neurogenesis
Synaptogenesis
Enhanced serotonergic neurotransmission
Anxiety reduction
Memory support
Neuroprotection
Protocol Reference
Dose
50-200mcg daily
Frequency
Once daily
Half-life
Approximately 23 hours
Route
Subcutaneous injection · Oral · Nasal
Evidence
Emerging
Research Models
Mouse
Also in Nootropic & Neuro